Review paper
Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis
More details
Hide details
Submission date: 2010-09-06
Final revision date: 2010-11-02
Acceptance date: 2010-12-01
Online publication date: 2011-05-17
Publication date: 2012-05-17
Arch Med Sci 2011;7(2):189–194
Antibodies to citrullinated proteins/peptides (ACPAs) are the second serological marker to have recently been included in the 2010 ACR/EULAR Rheumatoid Arthritis (RA) Classification Criteria, which are focused on early diagnosis and therapy. This review discusses their history and some clinical aspects of ACPAs, focusing on the diagnostic utility of anti-cyclic citrullinated peptide (anti-CCP) antibodies as a marker of RA as compared to the widely used rheumatoid factor (RF). Simultaneously, this review aims to raise physician awareness and interest in anti-citrullinated vimentin antibody (anti-Sa/anti-MCV), another member of the ACPA family, which appears to have a better predictive value as a marker of RA than anti-CCP or RF and correlates closely with disease activity and therapeutic response among patients with RA.